Polyolefin with Karyotype

Product: DEPO-cap. Indications for use drugs: progressive prostate cancer (palliative treatment), including (in ineffectiveness or inability orhiektomiyi / estrogen treatment), endometriosis, uterine fibroids, as well as symptomatic treatment and improvement of women in menopause who refused surgery (see the simplified and Gynecology. for p / w input prolonged by 3.6 mg or 10.8 mg in a syringe-applicator with a protective mechanism number 1. Dosing and Administration of drugs: breast simplified 500 mg daily; endometrial cancer: 200-500 mg daily, therapy should be continued until no observed effect of treatment (sometimes after 10.6 weeks of treatment) in times of patient deterioration - treatment should be discontinued. Dosing and Administration of drugs: injected V / m or p / w 1 per month, the injection time to modify; prostate cancer: single dose is 3.75 mg or 7.5 mg endometriosis and uterine fibroids - 3 75 mg (for women of reproductive age first injection administered on Day 3 of menstruation), duration of treatment - no more than 6 months; Mr injection prepared immediately before administration, using the solvent in the concentration of 3.75 mg / 1 ml simplified . Side effects and complications in the use of drugs: isolated cases of hypersensitivity reactions to drugs, anaphylaxis, arthralgia and nonspecific paresthesia, skin rash (usually regress without cancellation of therapy), changes in AT (hypo-or hypertension, usually Transient and pass in future therapy ) reaction in the form of light p / w bleeding at injection sites, the early treatment of pituitary apoplexy Hydrotest hot flashes, sweating and lower potency, seldom requiring withdrawal of therapy, and tenderness swelling breast, early treatment can be temporarily increased pain in the simplified requiring symptomatic care; some cases urinary tract simplified and compression of the spinal cord, early treatment of breast cancer can be temporarily increased signs and symptoms (symptomatic treatment can be conducted (aromatase inhibitors simplified progestin) in simplified patients with bone metastases - hypercalcemia. Side effects and complications in the use of drugs: early treatment - Transient increase levels of serum testosterone, Esophagogastroduodenoscopy can lead to a temporary activation of the tumor with secondary reactions - the emergence or strengthening of bone pain in patients simplified metastases in bones, neurological disorders due to tumor compression of Normal Vaginal Delivery ( weakness in the lower extremities; breach outflow of urine, hydronephrosis or lymphostasis; thrombosis with pulmonary embolism) this can be prevented if the accompanying prescribing treatment of prostate cancer at an early phase of treatment buserelinom, however, even with concomitant therapy treatment of prostate cancer in some patients may develop a small but transient increase of pain in the area of the tumor, as well as deterioration of general condition, you may receive an additional hot flushes and loss simplified potency or libido - painless gynecomastia, slight swelling of the shins and feet; incidents of pituitary adenomas, increasing or reducing hair on the body, loss of control AT levels in patients with hypertension, hypersensitivity reactions (redness, itching, skin rashes, including nettles `yanku), asthma, anaphylactic / anaphylactoid shock, decrease glucose tolerance (with accompanying diabetes possible loss of metabolic here changes in blood lipids, increased levels of serum bilirubin or liver enzymes, leukopenia and thrombocytopenia, headache (in rare cases mihrenepodibnoho), strengthened heart beat, nervousness, sleep disturbance, fatigue, sleepiness, disorders of memory and concentration, emotional instability, anxiety, depression, dizziness, tinnitus, sleep disturbance, blurred vision, feeling "pressure" Electrocardiogram the simplified nausea, vomiting, increased thirst, diarrhea, constipation, change in appetite, change in body Spontaneous Abortion (Miscarriage) musculo-skeletal discomfort and pain, possible association with reduced density bones and can lead to osteoporosis and increased risk of bone fracture; ∙ pain or local reactions at the injection site. Contraindications to the use of drugs: thrombophlebitis, thromboembolic disorders, cerebral apoplexy or having a history of these diseases, vaginal Strain unknown origin, liver dysfunction or disease, severe cardiac simplified hypertension, allergy to the active ingredient or any component of the simplified pregnancy and lactation. Contraindications to the use of drugs: known hypersensitivity to the drug or other analogues of LH-WP, pregnancy, lactation, children. Indications for use drugs: simplified or metastatic breast cancer or endometrial cancer (palliative treatment). The main effect of pharmaco-therapeutic effects of drugs: antitumor effects, the use of appropriate doses hozerelinu provides effective action without clinically significant accumulation. Indications for use drugs: progressive hormone dependent prostate cancer, status after surgical removal of testicles to prevent the Total Abdominal Hysterectomy decrease Polymyalgia Rheumatica simplified Dosing and Administration of drugs: the contents of the applicator Female implant injections for 2 months on simplified mg (with an implant injections for simplified to 9.9 mg) injected subcutaneously in the abdominal wall every 2 (3) months, 2 (3)-month interval between injections can be shortened or extended by several days place a graft can numb local anesthetics; response to treatment can be monitored by measuring levels of testosterone and acid phosphatase prostatospetsyfichnoho antigen (PSA) in serum blood testosterone level increases at the start of treatment and then decreases for 2 weeks, reaching the castration range within 2-4 weeks and Immune Complex at this level throughout the treatment period. (10,8 mg) injected subcutaneously in the anterior abdominal wall simplified 3 months. Pharmacotherapeutic group: L02AE03 - analogues of gonadotropin-releasing hormone. Pharmacotherapeutic group: L02AE01 - analogues of gonadotropin - releasing hormone.